Khodabakhshi Reza, Yahyazadeh-Jabbari Seyed H, Gohari Mahmod R, Shahidi Javad, Ameri Ahmad
Department of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran.
Saudi Med J. 2008 Dec;29(12):1735-8.
To study the response rate for common chemotherapy regimens, and the progression free survival analysis in ovarian cancer in Tehran.
Ninety-eight women with confirmed ovarian cancer who had surgery, followed by chemotherapy at the 3 hospitals in (Fayazbakhsh, Shohadayee Tajrish, and Imam-Hossein), Tehran, Iran, between 1997 and 2003 were enrolled in this retrospective descriptive study. Data regarding age, pathologic variations, surgical procedures, chemotherapy regimens, response rates, and time to progression of the disease were collected. Response rate was evaluated for 51 patients with epithelial cancer.
From a total of 98 patients, there were 81 (82.6%) epithelial, 12 (12.2%) germ cell, 4 (4.1%) granulosa cell tumors, and one case of lymphoma. Staging with optimal residue was performed for 18 patients. Stage III was the most common stage (44.9%). In 71.4% of patients, complete or partial response was seen, while the other patients showed stable, or progressive disease. The most important prognostic factors were the initial stage (p=0.034), and the extent of surgical procedure (p=0.045). Median disease-free survival was 52.6 months. Although, higher response rate was produced by taxane-based regimen in comparison with cisplatin-cyclophosphamide regimen (78.2 % versus 71.4%), but it was not statistically significant (p=0.275). Median age (49.6 years) of our patients is lower than expected. Besides, a large proportion of the patients are referred in advanced stages.
New chemotherapy practically has made no significant higher response rate.
研究德黑兰卵巢癌常见化疗方案的缓解率及无进展生存期分析。
本回顾性描述性研究纳入了1997年至2003年间在伊朗德黑兰的3家医院（法亚兹巴赫什医院、塔吉什烈士医院和伊玛目侯赛因医院）接受手术及后续化疗的98例确诊卵巢癌女性患者。收集了有关年龄、病理变化、手术方式、化疗方案、缓解率及疾病进展时间的数据。对51例上皮性癌患者的缓解率进行了评估。
98例患者中，有81例（82.6%）为上皮性癌，12例（12.2%）为生殖细胞肿瘤，4例（4.1%）为颗粒细胞瘤，1例为淋巴瘤。18例患者进行了最佳残留分期。Ⅲ期是最常见的分期（44.9%）。71.4%的患者出现完全或部分缓解，其他患者表现为疾病稳定或进展。最重要的预后因素是初始分期（p = 0.034）和手术范围（p = 0.045）。无病生存期的中位数为52.6个月。虽然与顺铂 - 环磷酰胺方案相比，紫杉烷类方案产生了更高的缓解率（78.2%对71.4%），但差异无统计学意义（p = 0.275）。我们患者的中位年龄（49.6岁）低于预期。此外，很大一部分患者就诊时已处于晚期。
新的化疗方案实际上并未使缓解率显著提高。
